NEW YORK – Women’s health diagnostic firm Progenity has hit bumps in the road in the eight years since it began, including multiple issues with the federal regulators and private insurers.
Meanwhile, its CEO tenure while he was at noninvasive prenatal testing firm Sequenom was also marred by a scandal.
Get the full story with
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.